Clinical presentation of olmesartan-induced enteropathy includes diarrhea, weight loss
Food and Drug Administration (FDA) is warning that the blood pressure drug
Last
Last updated on May 29, 2023
In August 2017, a $300 million settlement was reached with Daiichi Sankyo on behalf of individuals who filed lawsuits after suffering sprue-like enteropathy and other gastrointestinal issues from Benicar, Benicar HCT, Azor and Tribenzor
Each patient in the study was using Benicar and
A 2001 study published in the Journal of of Pharmacology found olmesartan to be safe and well tolerated at doses of up to 160 mg/day
Read About Blood Pressure Drug Lawsuits
Benicar has allegedly increased the risk of several gastrointestinal problems in its users
Gastrointestinal issues, such as belching, diarrhea, fat in stool, heartburn, indigestion, nausea, vomiting, or flatulence
After discontinuing the Benicar treatments, the Olmesartan and Celiac Disease-Like Symptoms
According to the MDL’s master long form complaint, plaintiffs claim Benicar led to the development of serious gastrointestinal conditions such as sprue-like enteropathy and villous atrophy
At times, sticking to a gluten-free diet tends to result in unappetizing dishes and an unsatisfying experience
This medication is taken by mouth, typically once per day
A new French study added to the mounting evidence that Benicar side effects can mimic the symptoms of celiac disease and IBS
Sprue-Like Enteropathy